Background-Low-density lipoprotein cholesterol (LDL-C) is the traditional measure of risk attributable to LDL. Nonhigh-density lipoprotein cholesterol (NHDL-C), apolipoprotein B (apoB), and LDL particle number (LDL-P) are alternative measures of LDL-related risk. However, the clinical utility of these measures may only become apparent among individuals for whom levels are inconsistent (discordant) with LDL-C. Methods and Results-LDL-C was measured directly, NHDL-C was calculated, apoB was measured with immunoassay, and LDL-P was measured with nuclear magnetic resonance spectroscopy among 27 533 healthy women (median follow-up 17.2 years; 1070 incident coronary events). Participants were grouped by median LDL-C (121 mg/dL) and each of NHDL-C, apoB, and LDL-P. Discordance was defined as LDL-C greater than or equal to the median and the alternative measure less than the median, or vice versa. Despite high LDL-C correlations with NHDL-C, apoB, and LDL-P (r=0. 910, 0.785, and 0.692; all P<0.0001), prevalence of LDL-C discordance as defined by median cut points was 11.6%, 18.9%, and 24.3% for NHDL-C, apoB, and LDL-P, respectively. Among women with LDL-C less than the median, coronary risk was underestimated for women with discordant (greater than or equal to the median) NHDL-C (age-adjusted hazard ratio, 2.92; 95% confidence interval, 2.33-3.67), apoB (2.48, 2.01-3.07), or LDL-P (2.32, 1.88-2.85) compared with women with concordant levels. Conversely, among women with LDL-C greater than or equal to the median, risk was overestimated for women with discordant (less than the median) NHDL-C (0.40, 0.29-0.57), apoB (0.34, 0.26-0.46), or LDL-P (0.42, 0.33-0.53). After multivariable adjustment for potentially mediating factors, including HDL cholesterol and triglycerides, coronary risk remained underestimated or overestimated by ≈20% to 50% for women with discordant levels. Prior studies in healthy individuals have suggested that cardiovascular risk may be more closely related to NHDL-C, apoB, or LDL-P than LDL-C [15] [16] [17] [18] [19] and that this difference is more clinically relevant when levels are discordant. [20] [21] [22] However, prior studies did not measure all of these parameters, nor did they directly measure LDL-C, relying instead on estimating LDL-C values from 3 other lipid measurements (total cholesterol, triglycerides, and HDL cholesterol), which may also introduce additional measurement error. 21, 22 Thus, the aim of the present study was to determine the prevalence and long-term prognosis of discordant levels of directly measured LDL-C compared with NHDL-C, apoB, or LDL-P among 27 533 apparently healthy women followed up for >17 years.
U nited States guidelines recommend measuring a standard lipid panel in adults and targeting lifestyle and lipidlowering therapy based on levels of low-density lipoprotein cholesterol (LDL-C). 1, 2 Furthermore, non-high-density lipoprotein cholesterol (NHDL-C), the cholesterol carried by LDL and VLDL particles and calculated as total cholesterol minus HDL cholesterol, is currently a secondary target of therapy in individuals with hypertriglyceridemia. 1 Recent guidelines from Europe 3, 4 and Canada, 5 as well as recent US consensus statements/recommendations, [6] [7] [8] [9] continue to endorse LDL-C as the primary lipid measure before and after treatment but acknowledge that NHDL-C or apolipoprotein B (apoB) could be recommended for individuals with hypertriglyceridemia or cardiometabolic abnormalities. February 4, 2014 Glasziou et al 14 have proposed that when evaluating a new test in relation to an old test, the consequences of the new test are best understood through the disagreements between the old and new tests (discordance analysis). Because there is significant controversy regarding when to use "new tests" such as NHDL-C, apoB, or LDL-P in clinical practice in relation to the "old test" (LDL-C), 1, 2 we aimed to examine the prognosis of individuals with discordant values of the new and old tests. In cases where the new and old tests are in agreement (concordant), such individuals may be best served by either test, and other considerations become important, including familiarity of clinicians with the test, widespread availability of the test, or cost considerations.
Prior studies in healthy individuals have suggested that cardiovascular risk may be more closely related to NHDL-C, apoB, or LDL-P than LDL-C [15] [16] [17] [18] [19] and that this difference is more clinically relevant when levels are discordant. [20] [21] [22] However, prior studies did not measure all of these parameters, nor did they directly measure LDL-C, relying instead on estimating LDL-C values from 3 other lipid measurements (total cholesterol, triglycerides, and HDL cholesterol), which may also introduce additional measurement error. 21, 22 Thus, the aim of the present study was to determine the prevalence and long-term prognosis of discordant levels of directly measured LDL-C compared with NHDL-C, apoB, or LDL-P among 27 533 apparently healthy women followed up for >17 years.
Methods

Study Population
Participants were drawn from the Women's Health Study, an ongoing prospective cohort that includes 28 345 initially healthy women. 23, 24 Participants were apparently healthy female healthcare professionals aged ≥45 years who were free of self-reported cardiovascular disease and cancer at study entry. At enrollment, women gave written informed consent and completed questionnaires on demographics, anthropometrics, medical history, and lifestyle factors. Women were also asked whether their mother or father had a myocardial infarction, and parental history of myocardial infarction before age 60 years was considered premature. 25 Of the 27 790 women with baseline lipid measurements, we excluded women with missing values for any of the lipid measurements (n=257), which left 27 533 women for analysis. The study was approved by the institutional review board of the Brigham and Women's Hospital (Boston, MA).
Laboratory Measurements
EDTA blood samples were obtained at enrollment and stored in vaporphase liquid nitrogen (−170° C). In a laboratory certified by the Lipid Standardization Program of the National Heart, Lung, and Blood Institute/Centers for Disease Control and Prevention, LDL-C was determined by a homogenous direct method from Roche Diagnostics (Indianapolis, IN). 26 Total and HDL cholesterol were determined by direct enzymatic colorimetric assays. Triglycerides were measured enzymatically with correction for endogenous glycerol. NHDL-C was calculated as total minus HDL cholesterol. ApoB was measured with an immunoturbidimetric assay (DiaSorin, Stillwater, MN). LDL-P (nmol/L) was measured by nuclear magnetic resonance spectroscopy with the Lipo-Profile-3 algorithm at LipoScience, Inc (Raleigh, NC).
27,28
Ascertainment of Coronary Events
The primary end point of interest was incident coronary events (nonfatal MI, percutaneous coronary intervention, coronary artery bypass grafting, or coronary death). Every 6 months for the first year and annually thereafter, women received follow-up questionnaires about the occurrence of end points. Nonfatal end points were based on selfreports from follow-up questionnaires, letters, or telephone calls. For each reported end point, we requested permission from the participant to examine the relevant medical records. A copy of the death certificate and additional records were requested as needed. Cases were reviewed by the Endpoints Committee and fulfilled the necessary confirmation criteria.
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Statistical Analysis
Statistical analyses were performed with Stata version 10.1 (StataCorp LP, College Station, TX). First, we determined medians and 25th and 75th percentiles for LDL-C, NHDL-C, apoB, and LDL-P. We calculated Spearman rank correlation coefficients (r) for LDL-C with each of NHDL-C, apoB, and LDL-P and examined them graphically with scatterplots. To examine the extent to which discordance or concordance of LDL-C and these alternative LDL measures was associated with risk, we categorized participants into categories according to less than or greater than or equal to median levels of LDL-C (121 mg/dL) and each of NHDL-C (154 mg/dL), apoB (100 mg/dL), and LDL-P (1216 nmol/L). Discordance was defined as LDL-C greater than or equal to the median and the alternative measure less than the median, or vice versa. We chose median cut points to define discordance to make it easier to apply clinically, because there is no physiological cut point for discordance. Differences between baseline characteristics of participants across these categories were analyzed with the Kruskal-Wallis rank test for comparing medians and ANOVA for comparing means of continuous measures. χ 2 Tests were used to analyze categorical variables.
We constructed cumulative probability curves for incident coronary events across the categories and tested for differences with the log-rank test. Absolute event rates were calculated per 1000 person-years. Cox proportional hazard models were used to calculate the hazard ratios and 95% confidence intervals. Ageadjusted and minimally and fully adjusted multivariate models were examined. The minimally adjusted models, which did not include other lipid or potentially mediating mechanisms, adjusted for age, randomized treatment assignment, hormone use, postmenopausal status, smoking, and blood pressure. The fully adjusted models additionally included diabetes mellitus, body mass index, HDL cholesterol, triglycerides, high-sensitivity C-reactive protein, and parental history of premature myocardial infarction. Finally, we repeated all analyses substituting Friedewald-estimated LDL-C instead of directly measured LDL-C after excluding the 592 women with triglycerides >400 mg/dL.
All reported P values were 2-tailed, and P<0.05 was considered statistically significant.
Results
Despite high correlations of LDL-C with NHDL-C, apoB, and LDL-P (Spearman r [95% confidence interval]: 0.910 [0.908-0.912], 0.785 [0.780-0.789], and 0.692 [0.686-0.698 ], respectively; all P<0.0001), the prevalence of LDL-C discordance (as defined by median cut points) with NHDL-C, apoB, and LDL-P was 11.6%, 18.9%, and 24.3%, respectively ( Figure 1 ). Although most individuals had concordant levels of LDL-C with NHDL-C ( Figure 1A ; top right and bottom left quadrants), apoB ( Figure 1B ), or LDL-P ( Figure 1C ), there were many individuals with discordant levels ( Figure 1 ; top left and bottom right quadrants).
To further characterize the clinical characteristics of individuals with discordant or concordant levels of LDL-C and each of the alternative LDL-related measures, we examined discordant or concordant subgroups according to LDL-C less than or greater than or equal to the median (Tables I-III in the online-only Data Supplement). Among discordant individuals, the concentration of LDL-C either underrepresented or overrepresented the concentration of NHDL-C, apoB, or LDL-P. As expected, individuals with concordantly low levels of LDL-C and either NHDL-C, apoB, or LDL-P had favorable risk factor profiles. By contrast, unfavorable risk profiles were noted for individuals with LDL-C below median but discordant (above median) levels of either NHDL-C, apoB, or LDL-P. These individuals had elevated triglycerides, low HDL cholesterol, and smaller LDL particles that were cholesterol depleted, in addition to having higher levels of highsensitivity C-reactive protein and increased body mass index compared with the other groups.
Furthermore, as expected, individuals with concordantly high levels of LDL-C and NHDL-C had unfavorable risk factor profiles. By contrast, despite having an LDL-C above median, individuals with discordant (below median) levels of either NHDL-C, apoB, or LDL-P had the lowest prevalence of smoking, hypertension, and diabetes mellitus and the lowest body mass index and high-sensitivity C-reactive protein levels. Moreover, these individuals had elevated LDL-C because their LDL particles were larger in size and more cholesterol enriched, despite having fewer overall numbers of LDL or apoB particles.
During a median follow-up of 17.2 years, a total of 1070 incident coronary heart disease events occurred. Among the 13 595 women with below-median LDL-C, coronary risk was underestimated by 3-fold for women whose level of LDL-C was discordant with NHDL-C (age-adjusted hazard ratio, 2.92; 95% confidence interval, 2.33-3.67) compared with being concordant (reference group; Figure 2 ; Table 1 ). Similar underestimation of coronary risk was observed for women with levels of LDL-C that were discordant with apoB (age-adjusted hazard ratio, 2.48; 95% confidence interval, 2.01-3.07) or with LDL-P (age-adjusted hazard ratio, 2.32; 95% confidence interval, 1.88-2.85; all P<0.0001). Coronary risk remained underestimated by ≈30% to 50% after full adjustment for other known risk factors, including potentially mediating factors such as diabetes mellitus, body mass index, HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein.
Conversely, for the 13 938 women with above-median LDL-C ( Figure 3 ; Table 2 ), coronary risk was overestimated by ≈3-fold when their LDL-C levels were discordant with NHDL-C, apoB, or LDL-P. Coronary risk remained overestimated by ≈20% to 40% in fully adjusted models, but this was statistically significant only for discordance of LDL-C with apoB.
When we repeated the analysis for discordance of LDL-C with all 3 alternative LDL-related measures simultaneously (ie, NHDL-C, apoB, and LDL-P), the underestimation or overestimation of coronary risk became more pronounced for women with LDL-C discordant with all 3 measures (Table IV in the online-only Data Supplement).
Alternatively, because some have proposed initial risk assessment with NHDL-C, apoB, or LDL-P instead of LDL-C, we reversed our analysis order and sought to determine the clinical utility of LDL-C as a second lipid measure. As shown Figure 2 . Cumulative probability of incident coronary heart disease (CHD) events among 13 595 women with low-density lipoprotein cholesterol (LDL-C) less than the median (121 mg/dL). As shown, coronary risk is underestimated for women with discordant (greater than or equal to the median) levels of non-high-density lipoprotein cholesterol (NHDL-C; 154 mg/dL), apolipoprotein B (ApoB; 100 mg/dL), or low-density lipoprotein particles (LDL-P; 1216 nmol/L) compared with concordant levels. Hazard ratios and 95% confidence intervals obtained from Cox regression models. P value for trend obtained from log-rank test.
(Figures I and II in the online-only Data Supplement), if either NHDL-C, apoB, or LDL-P was obtained as the initial test, then the effect of discordance with LDL-C on coronary risk was negligible.
Additional Analysis With Friedewald LDL-C
When the analyses were repeated with Friedewaldcalculated LDL-C (median 127 mg/dL) instead of directly measured LDL-C, we further excluded the 592 participants with triglycerides >400 mg/dL. 26 Among these 26 940 participants, the age-adjusted and minimally adjusted results were similar to the results shown in Tables 1 and 2 , which were obtained by directly measured LDL-C, whether for women with LDL-C below median or above median. However, among women with Friedewald LDL-C below median, the fully adjusted hazard ratio (95% confidence interval) for discordant NHDL-C was attenuated and no longer significant (1.30, 0.92-1.84; P=0.14) , whereas the fully adjusted results for discordant apoB (1.45, 1.09-1.92; P=0.01) or discordant LDL-P (1.42, 1.09-1.86; P=0.01) were slightly strengthened and remained statistically significant. Furthermore, in fully adjusted models, among women with Friedewald LDL-C above median, having discordantly low NHDL-C, apoB, or LDL-P was no longer statistically significant.
Discussion
In this study of apparently healthy women, we observed that the prevalence of discordance defined according to median concentrations of LDL-C with either NHDL-C, apoB, or LDL-P was common, reaching nearly 25% for LDL-P. Among discordant individuals, the concentration of LDL-C either underrepresented or overrepresented the concentration of NHDL-C, apoB, or LDL-P. Furthermore, among these discordant individuals, coronary risk was also either underestimated or overestimated by LDL-C. These data support the concept that for most individuals with concordant levels of LDL-C and an alternative LDL-related measure (NHDL-C, apoB, or LDL-P), the clinical utility of these measures is similar. However, among the subgroup of individuals (up to a quarter of the present study population) with discordance of LDL-C with another LDL-related Median values of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (NHDL-C), apolipoprotein B (apoB), and low-density lipoprotein particles (LDL-P) were 121 mg/dL, 154 mg/dL, 100 mg/dL, and 1216 nmol/L, respectively. CI indicates confidence interval; and HR, hazard ratio. *Minimally adjusted model included age, treatment assignment, hormone use, postmenopausal status, smoking, and blood pressure. †Minimally adjusted model variables plus diabetes mellitus, body mass index, high-density lipoprotein cholesterol, triglycerides, high-sensitivity C-reactive protein, and parental history of premature myocardial infarction. by guest on April 24, 2017 http://circ.ahajournals.org/ Downloaded from February 4, 2014 measure, risk may be overestimated or underestimated when one relies on LDL-C alone.
Although LDL-C and alternative LDL-related measures are closely correlated, they reflect different aspects of LDL. LDL-P is the number of LDL particles, whereas LDL-C is the amount of cholesterol carried by these LDL particles. Similarly, apoB is the number of apoB particles (most of which are LDL), whereas NHDL-C is the amount of cholesterol carried by these apoB particles. Mechanistically, the cholesterol content of LDL particles can vary substantially (>2-fold) across individuals because of differences in particle size, as can their relative content of cholesterol ester and triglycerides.
29 Accordingly, at any particular LDL-C concentration, individuals may have higher or lower concentrations of LDL particles, as reflected in their concentrations of NHDL-C, apoB, or LDL-P. Discordantly high NHDL-C, apoB, or LDL-P generally reflects increased concentrations of smaller, cholesterol-depleted LDL particles that predominate in the presence of high triglycerides, low HDL cholesterol, and insulin resistance. Not surprisingly, the increased risk associated with discordantly high NHDL-C, apoB, or LDL-P in the present study was attenuated after adjustment for these traits. However, even after adjustment, systematic underestimation of risk remained substantial for such discordant women.
To the best of our knowledge, this is the first report to assess LDL-C with all 3 proposed alternative LDL-related measures (NHDL-C, apoB, and LDL-P) in the same population and to compare them with directly measured LDL-C. Previously, when discordance analysis was used to compare Friedewald-estimated Figure 3 . Cumulative probability of incident coronary heart disease (CHD) events among 13 938 women with low-density lipoprotein cholesterol (LDL-C) greater than or equal to the median (121 mg/dL). As shown, coronary risk is overestimated for women with discordant (less than the median) levels of non-high-density lipoprotein cholesterol (NHDL-C; 154 mg/dL), apolipoprotein B (ApoB; 100 mg/dL), or low-density lipoprotein particles (LDL-P; 1216 nmol/L) compared with concordant levels. Hazard ratios and 95% confidence intervals obtained from Cox regression models. P value for trend obtained from log-rank test.
by guest on April 24, 2017 http://circ.ahajournals.org/ Downloaded from LDL-C with apoB and NHDL-C among men in the Quebec Cardiovascular Study, results favored apoB and NHDL-C over LDL-C. 20 Subsequently, 2 discordance analyses of Friedewaldestimated LDL-C versus LDL-P were conducted in the Framingham study and the Multi-Ethnic Study of Atherosclerosis, both of which favored LDL-P over LDL-C among discordant individuals. 21, 22 Although Friedewald-estimated LDL-C is used routinely for clinical practice, it requires 3 primary measurements (total cholesterol, HDL cholesterol, and triglycerides), which potentially decreases the accuracy and precision of the derived LDL-C concentration. In the present study, we measured LDL-C directly and thus avoided assay imprecision on this basis.
Additional strengths of the present study include its large sample size and long follow-up, which allowed for accrual of an adequate number of events among participants in the subgroups of discordant LDL categories; however, because we studied an apparently healthy cohort of women at low overall risk for coronary heart disease events, the present results may not be generalizable to men or other patient groups. Furthermore, the present data do not address the question of clinical utility for risk assessment and treatment strategies for higher-risk patients, such as those with known coronary heart disease, or for the monitoring of patients taking lipid-altering therapy. Such studies need to be performed in the appropriate patient settings, preferably within the context of randomized trials of primary or secondary prevention.
Despite following 27 533 women for >17 years, the present study was not structured to address specific differences between NHDL-C, apoB, and LDL-P; when compared to LDL-C among discordant women, the confidence intervals for all 3 of these alternative lipid measures overlap each other. However, the proportion of women found to be discordant with each measure varied >2-fold, with the highest rate observed for LDL-P.
In conclusion, among initially healthy women, variations in long-term coronary risk may stem in part from differences between their baseline levels of LDL-C and other LDL-related measures such as NHDL-C, apoB, or LDL-P. For the majority of women with concordant LDL measures, LDL-C has similar clinical utility to NHDL-C, apoB, or LDL-P, but for women with discordant LDL-related measures, coronary risk may be systematically overestimated or underestimated when one Median values of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (NHDL-C), apolipoprotein B (apoB), and low-density lipoprotein particles (LDL-P) were 121 mg/dL, 154 mg/dL, 100 mg/dL, and 1216 nmol/L, respectively. CI indicates confidence interval; and HR, hazard ratio. *Minimally adjusted model included age, treatment assignment, hormone use, postmenopausal status, smoking, and blood pressure. †Minimally adjusted model variables plus diabetes mellitus, body mass index, high-density lipoprotein cholesterol, triglycerides, high-sensitivity C-reactive protein, and parental history of premature myocardial infarction. by guest on April 24, 2017 http://circ.ahajournals.org/ Downloaded from February 4, 2014 relies on LDL-C alone. Thus, the present results support the use of alternative lipid testing among such discordant women.
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Supplemental Figure 2 . Cumulative probability of incident CHD events by concordant and discordant LDL-C among women with ≥ median NHDL-C, apoB, or LDL-P. Median values of LDL-C, NHDL-C, apoB, and LDL-P were 121 mg/dL, 154 mg/dL, 100 mg/dL, and 1216 nmol/L, respectively. Hazard ratios and 95% confidence intervals obtained from Cox regression models. P for trend obtained from log-rank test.
